认知未受损老年人日常功能变化与tau及淀粉样蛋白的关联
本研究基于抗淀粉样蛋白药物试验及其筛选失败者,分析1707名认知未受损老年人日常功能变化与淀粉样蛋白和tau PET的关系。结果显示,在淀粉样蛋白升高者中,新皮层和内嗅皮层tau水平最高者日常功能下降最明显,且tau增加与功能下降中度相关;单纯淀粉样蛋白未见功能变化。
要点
- 淀粉样蛋白升高者中,tau水平越高日常功能下降越快。
- tau累积与日常功能下降中度相关,单纯淀粉样蛋白无此关联。
- 复杂活动和购物支付困难是末次访视最常报告的功能减退。
核心结论
- 在淀粉样蛋白升高的认知未受损老年人中,tau水平越高日常功能下降越快。
- tau累积越多,日常功能下降速度越快,而单纯淀粉样蛋白未见功能变化。
研究设计与样本
- 前瞻性研究,纳入240周抗淀粉样蛋白药物随机对照试验参与者及因淀粉样蛋白PET阴性筛选失败者,共1707人(71.5±4.7岁,60%女性)。
- 其中434人 subset 接受重复tau PET扫描,参与者和研究伙伴多次完成ADCS ADL-PI量表。
- 采用广义最小二乘模型(限制性最大似然法)分析日常功能变化与淀粉样蛋白和tau PET的关系。
主要发现
- 1707名参与者日常功能呈边缘性下降。
- 淀粉样蛋白升高者中,新皮层和内嗅皮层tau最高者日常功能下降最大(参与者和研究伙伴报告)。
- 新皮层和内嗅皮层tau增加与ADCS ADL-PI评分下降中度相关(相关系数-0.2至-0.5)。
- 单纯淀粉样蛋白未见功能变化。
- 末次访视时,参与者和研究伙伴最常报告完成复杂活动及购物时选择和支付物品的困难增加。
临床怎么用
- 在临床实践和临床试验中,临床前AD阶段应纳入敏感的日常功能测量。
- 关注淀粉样蛋白升高且tau累积者的日常功能下降,尤其是复杂活动和购物支付能力。
局限性
- 部分参与者为筛选失败者,可能影响样本代表性。
- 仅434人接受重复tau PET扫描,亚组样本量有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: Everyday functioning declines gradually over time in Alzheimer disease (AD), with the earliest changes potentially occurring at the preclinical stage. We investigated how changes in everyday functioning relate to (changes in) amyloid and tau in a large sample of cognitively unimpaired older adults, most of whom had elevated amyloid levels at the start of the study. METHODS: This prospective study included participants from a 240-week randomized controlled trial of an anti-amyloid drug, solanezumab, and individuals who screen-failed because of a negative amyloid PET scan. A subset (n = 434) underwent repeated tau PET scans. Participants and their study partners completed the Alzheimer's Disease Cooperative Study Activities of Daily Living Prevention Instrument multiple times during the double-blind phase of the trial. Using generalized least-squares models, fit by restricted maximum likelihood, we analyzed how changes in everyday functioning related to amyloid and tau PET. We also correlated changes in amyloid and tau PET with changes in everyday functioning. RESULTS: A total of 1,707 participants (71.5 ± 4.7 years, 60% female) showed a marginal decline in everyday functioning. Among individuals with elevated amyloid, those with the highest levels of neocortical and medial temporal tau showed the largest decline in everyday functioning, as reported by the participants and their study partners. Increases in neocortical and medial temporal tau correlated moderately (correlation coefficient ranging from -0.2 to -0.5) with a decline in ADCS ADL-PI scores. Functional changes were not evident with amyloid alone. At the item level, participants and their study partners were most likely to report increased difficulty at the last visit with completing complex activities and selecting and paying for items when shopping. DISCUSSION: Higher tau levels are associated with the fastest decline in everyday functioning in the presence of elevated amyloid, and those accumulating more tau show a faster decline in everyday functioning. These findings demonstrate the utility of including sensitive measures of everyday functioning in clinical practice and clinical trials at the stage of preclinical AD. TRIAL REGISTRATION INFORMATION: The A4 study, ClinicalTrials.gov ID: NCT02008357; and Longitudinal Evaluation of Amyloid Risk and Neurodegeneration, ClinicalTrials.gov ID: NCT02488720.
引用
- Dubbelman MA, Liu A, Donohue MC, et al. Changes in Daily Functioning in Association With Tau and Amyloid Among Unimpaired Older Adults With and Without Elevated Amyloid. Neurology. 2025. PMID: 40440591. doi:10.1212/WNL.0000000000213775
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。